secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)
CIK:        0000315545
Form:       8-K
Filed at:   2022-09-26T23:59:59+00:00
Accession:  0001493152-22-026781
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Provectus Biopharmaceuticals approves up to $5M convertible note financing
--------------------------------------------------------------------------

- Board approved term sheet for up to $5M in convertible notes; proceeds fund drug discovery and G&A.
- Notes bear 8% interest, mature in 12 months, convertible into Series D-1 Preferred at $2.8620/share.
- Series D-1 Preferred shares convert into 10 common shares each.
- Company also closed $2.335M from previously disclosed 2021 convertible note financing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/315545/000149315222026781/0001493152-22-026781-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/315545/000149315222026781/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-026781

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer